New NICE Result: Lorlatinib

posted in: NICE News | 0

BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in adults who have not had an ALK inhibitor (1st line, CROWN indication). This recommendation … Read More

Trainee Enews October 2023

posted in: Trainee News | 0

Welcome to the inaugural BTOG trainee newsletter, where we aim to provide you with updates relevant to trainees working in the thoracic oncology space. In terms of content, the trainee newsletter will seek to summarise the ‘hot-off-the-press’ landmark papers, list … Read More

BTOG Steering Committee update  

posted in: News | 0

BTOG wishes to thank steering committee members, who have recently stepped down, for their commitment and valuable contribution.  BTOG also wishes to thank Sara Hiom, who recently stepped down as a Trustee, for service and commitment since 2016.   BTOG welcomes … Read More

New NICE Approval: Selpercatinib

posted in: NICE News | 0

BTOG wishes to inform members of a new NICE approval that has been published today.NICE has appraised selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer and BTOG is delighted it has been given a positive recommendation for the following:  … Read More

1 2 3 4 5 9